Common use of Estimated Project Timeline Clause in Contracts

Estimated Project Timeline. The outlined plan below reflects our current assessment of the development time required to complete the project. Gene Synthesis by Third Party [ ** ]. Project Kick-off Technology Transfer [ ** ] and data [ ** ] Selexis SUREtech Expression Vectors™ [ ** ] Development of High-Performance Clonal Cell Line(s) (LD2) u Note: - Xxxx boxes ¨ represent variability in delivery timing due to [ ** ]. ** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Date: April 12, 2010 33 of 39 Neogenix Oncology, Inc. Selexis SA

Estimated Project Timeline. The outlined plan below reflects our current assessment of the development time required to complete the project. Gene Synthesis by Third Party [ [** ]. *] Project Kick-off Technology Transfer [ ** ] and data [ ** ] Selexis SUREtech Expression Vectors™ [ ** ] Development of High-Performance Clonal Cell Line(s) (LD2) u Note: - Xxxx boxes ¨ represent variability in delivery timing due to [ ** ]. ** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Date: April August 12, 2010 33 2009 31 of 39 37 Neogenix Oncology, Inc. Selexis SA

Estimated Project Timeline. The outlined plan below reflects our current assessment of the development time required to complete the project. Gene Synthesis by Third Party [ ** ]. Project Kick-off Technology Transfer [ ** ] and data [ ** ] Selexis SUREtech Expression Vectors™ [ ** ] Development of High-Performance Clonal Cell Line(s) (LD2) u Note: - Xxxx boxes ¨ represent variability in delivery timing due to [ ** ]. ** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Date: April August 12, 2010 2009 33 of 39 Neogenix Oncology, Inc. Selexis SA